Samarjit Patnaik joined NIH in early 2009 and now works at NCATS on a chemistry team led by Juan J. Marugan, Ph.D. Patnaik focuses primarily on developing drug-like small molecule probes, mostly derived from high-throughput screening hits, to interrogate novel targets and pathways in cellular and animal disease models with a focus on rare and neglected diseases. He also devises chemical tools that facilitate target deconvolution from phenotypic assays. His work has led to the out-licensing of a class of noninhibitory chaperones for glucocerbrosidase as a prospective therapy for Gaucher disease and the initiation of a collaboration with the National Cancer Institute’s Experimental Therapeutics program for the preclinical development of perinucleolar compartment inhibitors as agents against cancer metastasis.
Before joining NCATS, Patnaik worked in the Oncology Medicinal Chemistry Division at GlaxoSmithKline, where his team developed the preclinical candidate GSK1838705A as a dual insulin growth factor-1 receptor/anaplastic lymphoma kinase inhibitor.
Patnaik received his B.Sc. in chemistry from St. Stephen’s College in Delhi, India, and a B.A. in natural sciences from Cambridge University. He received a Ph.D. in organic chemistry at Indiana University.
- Lysosomal storage disorders (Gaucher, Niemann-Pick type C, mucolipidosis type IV)
- Cancer (Eya2/Six1, perinucleolar compartment)
- Ion channels: TRPV1 (pain), TRPML1 (lysosomal storage disorder ML4)
- G-protein coupled receptor (neuropeptide S receptor, addiction)